Corvus Pharmaceuticals director Ian Clark to resign
Corvus Pharmaceuticals, Inc. reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the company’s board of directors, effective July 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Corvus Pharmaceuticals, Inc. reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the company’s board of directors, effective July 22, 2026. The company acknowledged and thanked Mr. Clark for his significant contributions during over nine years of board service.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation notice date: July 21, 2026
Resignation effective date: July 22, 2026
Board service tenure: over nine years
3 metrics
Resignation notice date
July 21, 2026
Date Ian T. Clark notified Corvus Pharmaceuticals of his intention to resign from the board
Resignation effective date
July 22, 2026
Effective date of Ian T. Clark's resignation from the board of directors
Board service tenure
over nine years
Length of Ian T. Clark's service on the Corvus Pharmaceuticals board
Key Terms
emerging growth company, Nasdaq Global Market, board of directors
3 terms
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Market market
"Common Stock, Par Value $0.0001 per share | CRVS | Nasdaq Global Market"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
board of directors financial
"intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Corvus Pharmaceuticals (CRVS) report on July 21, 2026?
Corvus Pharmaceuticals reported that director Ian T. Clark delivered notice on July 21, 2026 of his intention to resign from the board of directors, with the resignation becoming effective on July 22, 2026.
When is Ian T. Clark’s resignation from the Corvus Pharmaceuticals (CRVS) board effective?
Ian T. Clark’s resignation from the Corvus Pharmaceuticals board is effective on July 22, 2026. He provided notice of his intention to resign on July 21, 2026, one day before the effective date specified in the report.
How long has Ian T. Clark served on the Corvus Pharmaceuticals (CRVS) board?
Ian T. Clark has provided over nine years of board service to Corvus Pharmaceuticals. The company specifically thanked him for his significant contributions over this extended tenure as a director on its board.
On which exchange is Corvus Pharmaceuticals (CRVS) common stock listed?
Corvus Pharmaceuticals’ common stock, par value $0.0001 per share, is listed on the Nasdaq Global Market under the trading symbol CRVS, as stated in the company’s securities registration information.
Who signed the July 2026 report for Corvus Pharmaceuticals (CRVS)?
The report was signed on behalf of Corvus Pharmaceuticals by Leiv Lea, the company’s Chief Financial Officer. The signature block is dated July 22, 2026, the effective date of Ian T. Clark’s resignation from the board.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates